558
Participants
Start Date
December 20, 2023
Primary Completion Date
May 23, 2026
Study Completion Date
May 23, 2026
Multivalent Pneumococcal Vaccine - Formulation 1
Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stages 2, 3, and 4).
Multivalent Pneumococcal Vaccine - Formulation 2
Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stages 2, 3, and 4).
20-valent pneumococcal conjugate vaccine (20vPnC)
20-valent pneumococcal conjugate vaccine (20vPnC)
Licensed pneumococcal comparator vaccine
A licensed pneumococcal comparator vaccine
Multivalent Pneumococcal Vaccine - Formulation 3
Multivalent pneumococcal conjugate vaccine
Multivalent Pneumococcal Vaccine - Formulation 4
Multivalent pneumococcal conjugate vaccine
Rochester Clinical Research, LLC, Rochester
Accellacare - Wilmington, Wilmington
Clinical Research Atlanta, Stockbridge
Indago Research & Health Center, Inc, Hialeah
Alliance for Multispecialty Research, LLC, Doral
AMR Clinical, Knoxville
AMR Clinical, Knoxville
Headlands Research - Detroit, Southfield
Optimal Research, Peoria
Alliance for Multispecialty Research, LLC, New Orleans
DM Clinical Research- Cyfair, Houston
DM Clinical Research, Tomball
Dynamed Clinical Research, LP d/b/a DM Clinical Research, Tomball
Dynamed Clinical Research, LP d/b/a DM Clinical Research, Sugar Land
Clinical Trials of Texas, LLC dba Flourish Research, San Antonio
IMA Clinical Research San Antonio, San Antonio
Headlands Horizons LLC, Brownsville
J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City
Lead Sponsor
Pfizer
INDUSTRY